GlassScriptPhysician profile
Mahendra Ghanta
NPI 1861656548
$20,875.26
in general payments reported to CMS, 2019-2025
50 companies · $4,215 in 2025
The $4,215 reported for 2025 was more than what 86% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $913 · 2022: $5,515 · 2023: $5,398 · 2024: $4,835 · 2025: $4,215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,405.13 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,885.56 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $1,857.46 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Mannkind Corporation | $1,322.82 | 2022-2025 | Afrezza |
| Medtronic, INC. | $1,271.61 | 2022-2025 | Inpen Smart Insulin Delivery System, Minimed 780g, Intellis Adaptivestim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,237.01 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Dexcom, INC. | $1,123.04 | 2022-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $1,009.20 | 2021-2024 | Farxiga |
| Ascensia Diabetes Care US INC. | $1,007.17 | 2023-2025 | |
| Radius Health, INC. | $907.95 | 2021-2025 | Tymlos |
| Corcept Therapeutics | $862.04 | 2021-2025 | Korlym |
| Abbott Laboratories | $833.70 | 2021-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $798.03 | 2022-2025 | |
| Amgen INC. | $771.52 | 2021-2025 | Evenity, Repatha, Prolia |
| Cequr Corporation | $700.19 | 2022-2025 | Cequr Simplicity |
| Sanofi-Aventis U.S. LLC | $654.82 | 2021-2025 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $545.45 | 2021-2025 | Isturisa, Signifor Lar |
| Abbvie INC. | $473.60 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $354.41 | 2021-2025 | Gvoke Hypopen |
| Insulet Corporation | $328.72 | 2022-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $285.06 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $258.58 | 2023-2025 | Strensiq |
| Esperion Therapeutics, INC. | $249.98 | 2022 | |
| Kyowa Kirin, INC. | $247.63 | 2023-2025 | Crysvita |
| Tandem Diabetes Care, INC. | $235.53 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ultragenyx Pharmaceutical INC. | $209.05 | 2022 | |
| Zealand Pharma US, INC. | $172.34 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $164.05 | 2024-2025 | |
| Amarin Pharma, INC. | $146.51 | 2021-2022 | |
| Antares Pharma, INC. | $127.40 | 2022-2023 | Xyosted, Tlando, Nocdurna |
| Eusa Pharma (US) LLC | $109.73 | 2022 | |
| Madrigal Pharmaceuticals | $84.09 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $63.89 | 2022 | |
| Averitas Pharma INC. | $58.12 | 2023-2025 | Qutenza |
| Sequel Med Tech, LLC | $56.16 | 2025 | Twiist |
| Organogenesis INC. | $55.39 | 2023 | Puraply |
| Soleno Therapeutics, INC. | $54.24 | 2025 | Vykat Xr |
| Becton, Dickinson and Company | $43.06 | 2022 | |
| Tolmar, INC. | $41.82 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $35.91 | 2022-2023 | Somatuline Depot |
| Rhythm Pharmaceuticals, INC. | $32.30 | 2025 | Imcivree |
| Acerus Pharmaceuticals Corporation | $31.56 | 2022 | |
| Pfizer INC. | $30.64 | 2024-2025 | |
| Almatica Pharma LLC | $24.25 | 2024 | Teriparatide |
| Halozyme INC | $21.18 | 2023 | |
| Beta Bionics, INC. | $19.95 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Nevro Corp. | $16.48 | 2021 | |
| Lifescan, INC. | $14.74 | 2022 | |
| Intuity Medical INC | $14.22 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $13.94 | 2024 | |
| Grt US Holding, INC. | $13.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahendra Ghanta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.